Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Basal Cell 3Pancreatic Neoplasms 2Neoplasms 2Basal Cell Nevus Syndrome 2Head and Neck Neoplasms 1Chondrosarcoma 1Bone Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 27Fluorouracil 25Oxaliplatin 21Cisplatin 19Leucovorin 17Bevacizumab 15130-nm albumin-bound paclitaxel 13Docetaxel 12Capecitabine 12Albumin-Bound Paclitaxel 12Paclitaxel 11Irinotecan 10Carboplatin 9pembrolizumab 7Radiotherapy 6Pemetrexed 6Nivolumab 6Erlotinib Hydrochloride 6Cyclophosphamide 6Trastuzumab 5Ramucirumab 5Ipilimumab 4Everolimus 4Crizotinib 4Cetuximab 4vandetanib 3trastuzumab deruxtecan 3sargramostim 3folfirinox 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma × IPI-926 × Clear all
NCT01383538 2017-08-08

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

University of California, San Francisco

Phase 1 Completed
15 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡